Endothelin receptor antagonists

Barst, R. J., D. Langleben, A. Frost, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169: 441-7, 2004

Benigni, A. and G. Remuzzi. Endothelin antagonists. Lancet 353: 133-8, 1999

Channick, R. N., G. Simonneau, O. Sitbon, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358: 1119-23., 2001

Giaid, A., M. Yanagisawa, D. Langleben, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732-9, 1993

Miyauchi, T. and T. Masaki. Pathophysiology of endothelin in the cardiovascular system. Annual Review of Physiology 61: 391-415, 1999

Ray, A., L. G. Hegde, A. Chugh, et al. Endothelin-receptor antagonists: current and future perspectives. Drug Discov Today 5: 455-64., 2000

Rubens, C., R. Ewert, M. Halank, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120: 1562-9., 2001

Rubin, L. J., D. B. Badesch, R. J. Barst, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896-903, 2002

Stewart, D. J., R. D. Levy, P. Cernacek, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114: 464-9., 1991